. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2018 May 16;27(7):728–736. doi: 10.1158/1055-9965.EPI-17-0573

TABLE 4.

Change in biomarkers following celecoxib treatment

Patients treated with Celecoxib (N=244)
		Cox-2 at baseline				15-PGDH at baseline
		high	low			present	absent
Cox-2 at recurrence	high	2 (0.8%)	18 (7.4%)	15-PGDH at recurrence	present	4 (1.6%)	11 (4.5%)
Cox-2 at recurrence	low	12 (4.9%)	212 (86.9%)	15-PGDH at recurrence	absent	24 (9.8%)	205 (84.0%)
P= 0.27				P= 0.03

Patients treated with Placebo (N=200)
		Cox-2 at baseline				15-PGDH at baseline
		high	low			present	absent
Cox-2 at recurrence	high	1 (0.5%)	14 (7.0%)	15-PGDH at recurrence	present	4 (2.0%)	18 (9.0%)
Cox-2 at recurrence	low	10 (4.9%)	175 (87.3%)	15-PGDH at recurrence	absent	13 (6.5%)	165 (82.5%)
P=0.41				P=0.37